N Mittmann1, J M Porter2, J Rangrej2, S J Seung3, N Liu2, R Saskin2, M C Cheung4, N B Leighl5, J S Hoch6, M Trudeau4, W K Evans7, K N Dainty8, C DeAngelis4, C C Earle9. 1. Health Outcomes and PharmacoEconomics ( hope ) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON. ; Department of Pharmacology, University of Toronto, Toronto, ON. ; International Centre for Health Innovation, Richard Ivey School of Business, Western University, London, ON. ; Applied Research in Cancer Control, Cancer Care Ontario, Toronto, ON. 2. Institute for Clinical Evaluative Sciences, Toronto, ON. 3. Health Outcomes and PharmacoEconomics ( hope ) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON. 4. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. 5. Princess Margaret Cancer Centre, University Health Network, Toronto, ON. 6. Applied Research in Cancer Control, Cancer Care Ontario, Toronto, ON. ; Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON. 7. McMaster University, Hamilton, ON. 8. Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON. 9. Institute for Clinical Evaluative Sciences, Toronto, ON. ; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON.
Abstract
OBJECTIVE: The objective of the present analysis was to determine the publicly funded health care costs associated with the care of breast cancer (bca) patients by disease stage. METHODS: Incident cases of female invasive bca (2005-2009) were extracted from the Ontario Cancer Registry and linked to administrative datasets from the publicly funded system. The type and use of health care services were stratified by disease stage over the first 2 years after diagnosis. Mean costs and costs by type of clinical resource used in the care of bca patients were compared with costs for a matched control group. The attributable cost for the 2-year time horizon was determined in 2008 Canadian dollars. RESULTS: This cohort study involved 39,655 patients with bca and 190,520 control subjects. The average age in those groups was 61.1 and 60.9 years respectively. Most bca patients were classified as either stage i (34.4%) or stage ii (31.8%). Of the bca cohort, 8% died within the first 2 years after diagnosis. The overall mean cost per bca case from a public payer perspective in the first 2 years after diagnosis was $41,686. Over the 2-year time horizon, the mean cost increased by stage: i, $29,938; ii, $46,893; iii, $65,369; and iv, $66,627. The attributable cost of bca was $31,732. Cost drivers were cancer clinic visits, physician billings, and hospitalizations. CONCLUSIONS: Costs of care increased by stage of bca. Cost drivers were cancer clinic visits, physician billings, and hospitalizations. These data will assist planning and decision-making for the use of limited health care resources.
OBJECTIVE: The objective of the present analysis was to determine the publicly funded health care costs associated with the care of breast cancer (bca) patients by disease stage. METHODS: Incident cases of female invasive bca (2005-2009) were extracted from the Ontario Cancer Registry and linked to administrative datasets from the publicly funded system. The type and use of health care services were stratified by disease stage over the first 2 years after diagnosis. Mean costs and costs by type of clinical resource used in the care of bca patients were compared with costs for a matched control group. The attributable cost for the 2-year time horizon was determined in 2008 Canadian dollars. RESULTS: This cohort study involved 39,655 patients with bca and 190,520 control subjects. The average age in those groups was 61.1 and 60.9 years respectively. Most bca patients were classified as either stage i (34.4%) or stage ii (31.8%). Of the bca cohort, 8% died within the first 2 years after diagnosis. The overall mean cost per bca case from a public payer perspective in the first 2 years after diagnosis was $41,686. Over the 2-year time horizon, the mean cost increased by stage: i, $29,938; ii, $46,893; iii, $65,369; and iv, $66,627. The attributable cost of bca was $31,732. Cost drivers were cancer clinic visits, physician billings, and hospitalizations. CONCLUSIONS: Costs of care increased by stage of bca. Cost drivers were cancer clinic visits, physician billings, and hospitalizations. These data will assist planning and decision-making for the use of limited health care resources.
Entities:
Keywords:
Breast cancer; costs; disease stage; population-based analysis
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Steven Broekx; Elly Den Hond; Rudi Torfs; Anne Remacle; Raf Mertens; Thomas D'Hooghe; Patrick Neven; Marie-Rose Christiaens; Steven Simoens Journal: Eur J Health Econ Date: 2010-03-20
Authors: Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Kelvin Chan; Stuart Peacock; Murray D Krahn Journal: CMAJ Open Date: 2013-01-16
Authors: Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Mahbubul Haq; Kelvin Chan; Winson Y Cheung; Jeffrey S Hoch; Stuart Peacock; Murray D Krahn Journal: CMAJ Open Date: 2013-12-09
Authors: Nicole Mittmann; Ning Liu; Joan Porter; Soo Jin Seung; Pierre K Isogai; Refik Saskin; Matthew C Cheung; Natasha B Leighl; Jeffrey S Hoch; Maureen Trudeau; William K Evans; Katie N Dainty; Craig C Earle Journal: CMAJ Open Date: 2014-02-04
Authors: Ashley C Mays; Harrison G Bartels; Paul R Wistermayer; Matt L Rohlfing; Christopher M Gentile; Ralph D'Agostino; Joshua D Waltonen Journal: Head Neck Date: 2017-11-13 Impact factor: 3.147
Authors: Aileen B Chen; Ling Li; Angel M Cronin; Gabriel A Brooks; Brian D Kavanagh; Deborah Schrag Journal: Health Serv Res Date: 2017-08-31 Impact factor: 3.402
Authors: Nicole Mittmann; Natasha K Stout; Pablo Lee; Anna N A Tosteson; Amy Trentham-Dietz; Oguzhan Alagoz; Martin J Yaffe Journal: Health Rep Date: 2015-12 Impact factor: 4.796